PR Newswire BiotechOriginal article
IASO Bio's CD20-Targeted In Vivo CAR-T Therapy IASO208 Receives FDA IND Clearance
RegulatoryapprovedIASO208Positive
AI Analysis
Summary
IASO Bio's CD20-targeted in vivo CAR-T therapy IASO208 has received FDA IND clearance, marking the first China-originated lentiviral vector-based in vivo CAR-T to achieve this milestone. The therapy is expected to advance into a Phase 1b clinical study in the United States, supported by early clinical data from an investigator-initiated trial in China.
Clinical Trial Data
Phase
1b
Outcome Details
FDA IND clearance received for IASO208, first China-originated lentiviral vector-based in vivo CAR-T therapy to receive FDA IND clearance
Importance:7/10
Sentiment:
0.80
CAR-T therapyin vivo CAR-Tlentiviral vectorCD20-targetedFDA IND clearanceChina-originatedPhase 1b
Read the original article
Published by PR Newswire Biotech on September 16, 2026 9:47 AM